Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus

Frontiers in Immunology

Immunology

Kai-Hung Hsiao¹  Hung-Ming Wu²  Yi-Giien Tsai³  Kuender D. Yang⁴  Ching-Yuang Lin⁵  Pei-Fen Liao⁶ 

[1] Department of Allergy, Immunology and Rheumatology, Changhua Christian Hospital, Changhua, Taiwan;Department of Neurology, Changhua Christian Hospital, Changhua, Taiwan;Department of Pediatrics, Changhua Christian Children’s Hospital, Changhua, Taiwan;School of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan;School of Medicine, Chung Shan Medical University, Taichung, Taiwan;Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan;Department of Pediatrics, Mackay Memorial Hospital, New Taipei City, Taiwan;Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan;Division of Pediatric Nephrology, Children’s Hospital, China Medical University Hospital, Taichung, Taiwan;School of Medicine, Chung Shan Medical University, Taichung, Taiwan;Division of Allergy, Asthma and Rheumatology, Department of Pediatrics, Chung Shan Medical University Hospital, Taichung, Taiwan;

关键词: systemic lupus erythematosus;    lupus nephritis;    regulatory T cells;    interleukin-2;    B regulatory cells;   

DOI  :  10.3389/fimmu.2023.1230264

 received in 2023-05-28, accepted in 2023-08-15,  发布年份 2023

来源: Frontiers

【 摘 要 】

Systemic lupus erythematosus (SLE) is a heterogeneous multisystem inflammatory disease with wide variability in clinical manifestations. Natural arising CD4+ regulatory T cells (Tregs) play a critical role in maintaining peripheral tolerance by suppressing inflammation and preventing autoimmune responses in SLE. Additionally, CD8+ regulatory T cells, type 1 regulatory T cells (Tr1), and B regulatory cells also have a less well-defined role in the pathogenesis of SLE. Elucidation of the roles of various Treg subsets dedicated to immune homeostasis will provide a novel therapeutic approach that governs immune tolerance for the remission of active lupus. Diminished interleukin (IL)-2 production is associated with a depleted Treg cell population, and its reversibility by IL-2 therapy provides important reasons for the treatment of lupus. This review focuses on the pathogenesis and new therapeutics of human Treg subsets and low-dose IL-2 therapy in clinical benefits with SLE.

【 授权许可】

Unknown   
Copyright © 2023 Tsai, Liao, Hsiao, Wu, Lin and Yang